Strand Life Sciences, a leading genomics and bioinformatics company and subsidiary of Reliance Industries, has launched CancerSpot, an innovative blood-based test for the early detection of multiple cancers. Using methylation profiling technology, the test identifies tumour DNA fragments in the blood, offering a non-invasive and efficient solution for proactive cancer screening.
CancerSpot operates with a simple blood sample and employs a proprietary genome sequencing and analysis process to detect DNA methylation signatures associated with cancer. The technology, derived from Indian cohorts, has demonstrated its robustness across global ethnicities, making it suitable for both domestic and international populations.
Isha Ambani Piramal, Member of the Board at Reliance Industries Limited, emphasised the test's transformative potential, saying, “Cancer in India is a major source of financial, social, and psychological burden. Strand’s CancerSpot exemplifies our vision to advance healthcare through pioneering genomic solutions. This innovation reflects Reliance’s ‘WE CARE’ philosophy, reinforcing our dedication to improving lives in India and beyond.”
The announcement coincided with the inauguration of Strand’s Genomics Diagnostics & Research Centre in Bengaluru, a 33,000 square-foot facility equipped with advanced sequencing technologies. Inaugurated by Dr. Charles Cantor, a global genomics expert, the centre is designed to foster collaboration among bioinformatics experts, molecular biologists, and clinicians.
Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, remarked, “Early detection is key to beating cancer. CancerSpot represents a milestone in India’s genomic capabilities and reflects our 24-year commitment to innovation. This new centre will accelerate research and deliver cutting-edge diagnostics for global and Indian populations.”
_20241226144814_original_image_13.webp)
